Healthcare / Pharmaceutical RetailersBSE
$249.15
-0.35 (-0.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-213.4M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
15.3x
↓EV/EBITDA
9.8x
↓ROE
19.0%
↑Gross Margin
40.7%
↓Debt/Equity
0.73
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+59.7%
FCF CAGR
—
FCF margin
-38.9%
FCF / Net income
-2.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.29B · net income $190.4M · FCF $-502.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.29B | $1.29B | $869.6M | $446.3M | $316.9M |
| Net Income | $190.4M | $190.4M | $117.5M | $63.4M | $60.2M |
| EBITDA | $373.8M | $373.8M | $230.9M | $102.4M | $73.2M |
| EPS | — | — | 10.22 | 5.52 | 6.22 |
| Gross Margin | 40.7% | 40.7% | 47.6% | 28.1% | 28.8% |
| Operating Margin | 17.1% | 17.1% | 10.8% | 18.7% | 19.6% |
| Net Margin | 14.8% | 14.8% | 13.5% | 14.2% | 19.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.73 | 0.73 | 0.84 | 0.35 | 0.17 |
| Current Ratio | 1.59 | 1.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-502.2M | $-502.2M | $-213.4M | $-156.7M | $-259.2M |
| Returns | |||||
| ROE | 19.0% | 19.0% | 18.2% | 12.0% | 13.2% |
| Valuation | |||||
| P/E | 15.27 | 15.27 | 25.64 | 28.99 | 23.47 |
| EV/EBITDA | 9.79 | 9.79 | 15.28 | 19.12 | 18.44 |
| P/B | 2.96 | 2.96 | 4.67 | 3.48 | 3.09 |
| Growth & Yield | |||||
| Revenue Growth | 48.4% | 48.4% | 94.9% | 40.8% | — |
| EPS Growth | — | — | 85.1% | -11.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.1%
Start / end P/E
n/dx → n/dx
EPS bridge
10.22 → n/d
Residual
-10.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.